gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · MBRXHealthcarePharmaceuticals

Moleculin Biotech, Inc. (MBRX)

$8.46+1.93%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$8.35▼ 96.79% in range
Nov 3, 2025Low $5.61 · High $259.85Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Moleculin Biotech closed at $8.46 on Nov 4, up 1.93%, 96.7% below its 52-week closing high. Volume of 13.8K shares was 0.07× its 20-day average (below normal).

Split-adjusted performance: -5.1% over one month, -82.9% over six months, -96.7% over one year.

Short interest was 126.3K shares at the Oct 15 settlement, down 38.3% from the prior report (0.7% of float, 1.0 days to cover).

Market cap$8.6M1.0M shares
Revenue · quarter$0.00—
Diluted EPS$-28.00—
P/E · TTM—
Net margin—
Dividend yieldNone
52-week range5.61 – 259.85−96.7% from high
Volume13.8K0.07× 20-day avg
Volatility · 60d850.7%Annualised
Short % of float0.7%1.0 days to cover
Net cash$7.3MCash $7.3M
Next earnings—Not scheduled
Split-adjusted performance
1W −3.3%1M −5.1%3M +9.9%6M −82.9%YTD −87.2%1Y −96.7%3Y −99.8%5Y −100.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum6
Revenue growth—
Net margin—
Value (low P/E)—
Size13

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short126.3K−38.3% vs prior
Days to cover1.0Settled Oct 15
% of float0.7%
Short vol. 10d54.6%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
MBRXMoleculin Biotech$8.46+1.93%−82.9%———$8.6M
LEXXLexaria Bioscience$4.07+0.99%−59.8%−100.0%——$8.6MCompare
TOVXTheriva Biologics$0.1900+4.40%−50.3%———$8.7MCompare
GTBPGT Biopharma$4.84−8.16%−51.9%———$8.7MCompare
LTRNLantern Pharma$0.5866−2.61%−72.6%———$8.8MCompare
MTVAMetaVia$1.34+6.35%−4.3%———$8.8MCompare
ACTUActuate Therapeutics$0.3699+5.69%−87.6%———$8.9MCompare
VTGNVistagen Therapeutics$0.1843+9.70%−69.8%+504.9%−882.8%—$8.2MCompare
CURXCuranex Pharmaceuticals$5.80−6.30%−17.7%———$9.1MCompare

News about Moleculin Biotech

All news →
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular MedicineGlobeNewswire Inc. · Sep 28, 2026▲ PositiveMoleculin Releases Next CEO Corner Segment Highlighting MIRACLE StudyGlobeNewswire Inc. · Mar 11, 2026▲ Positive

Quick answers

What does Moleculin Biotech do?
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions.
What is MBRX's market cap?
$8.62M, based on the Nov 4 close of $8.46.
Does Moleculin Biotech pay a dividend?
No regular cash dividend has been paid in the last year.
How much of MBRX is sold short?
126.3K shares, 0.7% of float, as of Oct 15, 2026.
What sector is MBRX in?
Healthcare, in the Pharmaceuticals industry.

About Moleculin Biotech

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

HQ: Houston, TX17 employeesListed Jun 2, 2016moleculin.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology